NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Variantyx

Variantyx

Private
Framingham, MassachusettsHealthcare & Life Scienceshttps://www.variantyx.com/

Last Round

VC Round

Apr 26, 2024

Total Funding Raised

$94.5M

Company Overview

Variantyx is a biotechnology company that provides whole genome sequencing and analysis services for diagnosing rare inherited disorders, reproductive health, and precision oncology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Medical AI, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

whole genome sequencingWGSmolecular diagnosticsprecision medicinegenetic testinggenomic analysisrare disease diagnosticsmedical AIclinical bioinformaticshereditary cancer testingprenatal genomicsgenomic interpretationdiagnostic odysseyAI diagnosticsgenomic medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Variantyx Comps

Public and private peers based on sector, stage, and business model.

Variantyx comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Variantyx Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundApr 26, 2024
Series COct 18, 2023
DebtOct 18, 2022
Series C ExtensionFeb 14, 2022
Series CMar 15, 2021
Series B
Jun 6, 2019

Key People

Founding team and executive leadership

Haim Neerman

Co-Founder And CEO

Founding Team

Variantyx Investors

Notable investors and investment history

Variantyx investors
InvestorRounds
Kreos CapitalDebt
Bosch VenturesVC Round, Series C, Series C Extension
New Era Capital PartnersVC Round, Series C, Series B, Series C Extension
Peregrine Ventures (California)VC Round
Kreos CapitalDebt
IBM VenturesSeries C
GF Financial Markets (UK) LimitedSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 14, 2025

    Launched proprietary Genomic Unity® testing platform for whole genome sequencing diagnostics.

  • Oct 14, 2025

    Company is a CLIA/CAP-certified genomics company.

Variantyx Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Variantyx Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Variantyx's valuation, stock price, and market status.

Firmographic Details

HeadquartersFramingham, Massachusetts
Employee Range226
Year Founded2014
Last FundingApr 26, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.